Related Experiment Video
Updated: Jun 28, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Update of lipid lowering therapy]
1Institut für Klinische Chemie und Hämatologie, Kantonsspital St. Gallen. walter.riesen@ikch.ch
Insights
Dyslipidemia significantly increases cardiovascular risk. Current guidelines recommend lipid-lowering therapy based on overall patient risk, with statins being a generally safe option when used appropriately.
Area of Science:
- Cardiology
- Metabolic Disorders
- Pharmacology
Context:
- Dyslipidemia is a major modifiable risk factor for cardiovascular disease.
- Effective lipid management is crucial for cardiovascular event prevention.
- Current guidelines emphasize a global risk assessment approach for initiating therapy.
Purpose:
- To outline the principles of lipid management in clinical practice.
- To discuss the selection of lipid-lowering therapies based on lipid profiles.
- To highlight considerations regarding target values and safety profiles of treatments.
Summary:
- Lipid management strategies should align with a patient's global cardiovascular risk.
- Therapeutic choices must be tailored to specific lipid abnormalities, considering efficacy and safety.
- Statins are commonly used but require monitoring for potential side effects like hepatotoxicity and myopathy.
- Lifestyle modifications are fundamental to all lipid management plans.
Impact:
- Informing clinical decision-making for optimizing dyslipidemia treatment.
- Improving patient outcomes by reducing cardiovascular risk through targeted lipid management.
- Guiding healthcare professionals in selecting appropriate and safe lipid-lowering therapies.
Abstract:
Dyslipidemia is one of the most important cardiovascular risk factors. Accordingly preventive measures to normalize lipids are of great importance. The indication for a lipid lowering therapy according to current guidelines focuses on the identification of a patient's global risk, i.e. the contribution of all major cardiovascular risk factors. The selection of the lipid lowering therapy should be appropriate for the kind of lipid disorder. This may be a special challenge with respect to target values and safety aspects. Statins in monotherapy are generally considered safe drugs. Higher dosages may be associated with liver toxicity and muscle problems. Lifestyle management should underpin all lipid management strategies.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Hypertension IV: Drug Therapy and Lifestyle Modifications
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...